01 GLP-1 Therapy Adoption The cardiometabolic disease market analysis shows that GLP-1 therapies support the market share of treatments for obesity and related cardiovascular risks. The shift toward medicines that address weight and metabolic health broadens treatment options for eligible patients. For example, the FDA approved Wegovy to reduce major cardiovascular risks in adults with cardiovascular disease and overweight or obesity; a trial recorded events in 6.5% of treated participants versus 8% receiving placebo.
02 AI-Assisted Medical Imaging The cardiometabolic disease market analysis shows that AI-assisted imaging supports the market share of technology-enabled diagnostic solutions. The transition toward AI-based image analysis helps clinicians identify patterns and support earlier assessment of cardiovascular conditions. The FDA’s authorized device list includes AI-enabled cardiovascular tools, such as software for cardiac amyloidosis detection using ECG data.
01 Sedentary Lifestyle Patterns and Chronic Kidney Disease Burden Drive Market Prolonged sitting and limited physical activity increase the risk of obesity, type 2 diabetes, and cardiovascular disorders, creating greater demand for preventive care and long-term treatment. For example, individuals with low physical activity may require regular blood glucose testing, cholesterol management, and cardiac risk assessments.The link between chronic kidney disease and conditions such as diabetes and hypertension increases the need for ongoing monitoring and coordinated treatment. For example, patients with diabetes-related kidney complications may require regular kidney function tests and cardiovascular care, supporting demand for diagnostic services and chronic disease management.
01 Shortage of Healthcare Professionals and Adverse Effects of Long-Term Medications Restrain Cardiometabolic Disease Market Expansion A shortage of cardiologists, endocrinologists, and other specialized healthcare professionals can delay diagnosis and limit access to timely treatment for cardiometabolic conditions. These capacity constraints can reduce patient monitoring and treatment continuity, slowing market adoption across underserved areas.Adverse effects such as dizziness, gastrointestinal discomfort, and the risk of complications from certain medications can make long-term treatment difficult for some patients. These concerns may lead to missed doses or treatment discontinuation, reducing adherence and limiting demand for sustained cardiometabolic disease management.
01 AI-Based Drug Discovery and Digital Therapeutics Platforms Offers Growth Opportunities Pharmaceutical companies, biotechnology firms, and research institutions benefit from AI tools that identify potential drug candidates and accelerate cardiometabolic treatment development. Drug discovery partnerships, licensing agreements, and research contracts create revenue opportunities for companies such as Insilico Medicine and Recursion Pharmaceuticals.Patients with diabetes, hypertension, and other cardiometabolic conditions benefit from digital programs that support disease management and treatment adherence. Software subscriptions, healthcare-provider partnerships, and employer wellness contracts create additional revenue avenues for companies such as Omada Health and DarioHealth, supporting cardiometabolic disease market growth.
June 2026 – Amgen Presents New Cardiometabolic Data at ADA 2026Amgen presented new clinical data across its cardiometabolic portfolio at the American Diabetes Association (ADA) Scientific Sessions. The company reported additional Phase III VESALIUS-CV findings showing Repatha® reduced first major cardiovascular events in high-risk diabetes patients and highlighted new real-world evidence addressing obesity and diabetes treatment gaps.
May 2026 – BioAge Labs Advances BGE-102 into Mid-Stage Cardiometabolic Clinical DevelopmentBioAge Labs announced positive Phase I results for BGE-102, an oral NLRP3 inhibitor targeting inflammation associated with cardiometabolic disease. The company confirmed plans to initiate a Phase II cardiovascular risk study during 2026 following strong reductions in inflammatory biomarkers.
March 2026 – Novo Nordisk Initiates REDEFINE-OUTCOMES Phase III Cardiovascular Outcomes TrialNovo Nordisk initiated the REDEFINE-OUTCOMES Phase III cardiovascular outcomes trial evaluating CagriSema in patients with obesity and established cardiovascular disease. The study aims to assess reduction in major adverse cardiovascular events while expanding the company's cardiometabolic treatment portfolio.
January 2026 – Eli Lilly and Nimbus Therapeutics Expand Collaboration for Oral Cardiometabolic MedicinesEli Lilly and Nimbus Therapeutics entered a multi-year collaboration to develop AI-enabled oral medicines targeting obesity and broader cardiometabolic diseases. The agreement combines Nimbus' computational drug discovery platform with Lilly's metabolic disease expertise to accelerate next-generation oral therapies.